A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer

Histologically or cytologically-proven new diagnosis of single primary bronchogenic Stage IIIA or selected Stage IIIB NSCLC. Pts with unresectable Stage IIIA (N2) disease must have both criteria outlined in Section 5.2. Pts with Stage IIIB disease must satisfy at least one of the criteria outlined in Section 5.3. Pts must not have two or more parenchymal lesions on same or opposite sides of the lung. Pts must not have pericardial or pleural effusions (excluding small pleural effusion too small to be tapped and/or visible only on CT or MRI alone). Pts may have primary tumor located within 1 cm of major vessel, no aortic involvement. Pts must be assessed for hemoptysis within 28 days prior. Pts must have recovered to < Grade 2 esophagitis before proceeding with consolidation. Must have pre-treatment simulation demonstrating V20 </= 35% with planned radiation dose of 6,480 cGy. Measurable disease must be assessed by chest CT or MRI within 28 days prior. Non-measurable disease must be assessed within 42 days prior. No brain mets. CT/MRI of brain within 42 days prior. CT scan of upper abdomen including liver and adrenals to exclude metastatic disease within 42 days prior. Must have IRB approval of S9925 and patients must be offered participation in S9925. No prior chemo, radiation, or curative surgery for this cancer. Adequate renal function with tests outlined in 5.15 within 28 days prior. Pulmonary function tests within 42 days prior. Within 28 days prior: ANC >/= 1,500/mcl; Platelets >/=100,000/mcl; 24-hr urine protein <1,000mg; INR <1.5. Zubrod 0-2. Pts must not have >/= Grade 2 neuropathy-sensory, history of CVA, myocardial infarction, unstable angina, uncontrolled hypertension, NYHA Grade 2 or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris, or peripheral vascular disease. Must be willing to provide smoking history. Must not have a high risk of bleeding from a condition other than lung cancer. Pts must not have hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies. Pts must not have non-healing wound, ulcer, or bone fracture. Must not require full-dose anticoagulation. No other prior malignancy except for those outlined in Section 5.28. No pregnant or nursing women.